Toxocariasis and Wells' syndrome: a causal relationship?

Wells' syndrome, also known as eosinophilic cellulitis, remains a poorly understood condition. Prior research has shown that multiple factors, including infections and immune disorders, may contribute to its development. However, no single cause has been consistently identified. The role of parasitic infections in triggering this syndrome has not been fully resolved. While some studies have suggested a link between parasitic agents and skin inflammation, the evidence remains inconclusive. Eosinophilia is a common feature, but its origin is unclear in many cases. The excretory-secretory antigens of parasites have been proposed as potential triggers for immune responses. Despite these observations, no definitive causal agent has been established. This uncertainty has motivated further investigation into possible infectious etiologies.

This study aimed to explore a potential causal link between Toxocara canis infection and Wells' syndrome. The authors sought to determine whether elevated antibody titers to Toxocara antigens correlated with clinical manifestations of the syndrome. They focused on patients with characteristic skin lesions and histological findings consistent with Wells' syndrome. The goal was to assess whether treatment targeting Toxocara could lead to clinical improvement. By comparing responses to albendazole treatment, the researchers aimed to evaluate the role of parasitic infection in disease activity. The study also aimed to distinguish between coincidental associations and true causal relationships. The presence of elevated antibody titers in some patients raised questions about their clinical significance. This investigation aimed to clarify the role of Toxocara in a subset of Wells' syndrome cases.

The study involved a case series of three patients with suspected Wells' syndrome. Clinical and histological assessments were conducted to confirm the diagnosis. Serum samples were tested for Toxocara-specific antibodies using excretory-secretory antigens. Patients with elevated antibody titers received oral albendazole treatment. Clinical outcomes were monitored for resolution of skin lesions and recurrence. Follow-up included repeated antibody titer measurements to assess serological response. A fourth patient with similar features but no clinical improvement was included for comparison. The study design allowed for direct evaluation of treatment response in relation to antibody levels.

Two patients with Wells' syndrome and elevated Toxocara antibody titers showed complete resolution of skin lesions after albendazole treatment. Their antibody titers normalized following treatment. In contrast, a third patient with similar antibody levels did not respond to albendazole. This patient's skin lesions persisted despite serological normalization. The differential response to treatment suggests a possible causal relationship in some cases. The presence of elevated antibody titers alone does not guarantee clinical benefit. The study highlights variability in treatment outcomes among patients with similar serological profiles. These findings support the hypothesis that Toxocara may contribute to disease activity in selected individuals.

The authors propose that Toxocara canis may play a causal role in a subset of Wells' syndrome cases. The observed clinical response to albendazole treatment supports this hypothesis. However, the lack of response in one patient indicates that the relationship is not universal. The study does not establish Toxocara as the sole cause of Wells' syndrome. Instead, it suggests a possible contributing factor in selected individuals. The normalization of antibody titers following treatment is consistent with a parasitic etiology. The results do not rule out other potential triggers of the syndrome. The findings may guide future diagnostic and therapeutic approaches in patients with eosinophilic skin lesions.